Abstract
Introduction
Vitamin D 3 is a lipid-soluble steroid hormone and the active metabolite 1.25(OH) 2 D 3 is crucial for calcium/phosphate homeostasis and bone metabolism [1] . Pre-vitamin D 3 is produced in the skin through rapid isomerization of 7-dehydrocholesterol after exposure to sunlight and is transported by vitamin D binding protein (DBP) to the liver following conversion into 25 (OH)D 3 by 25-hydroxylase (Cyp27a1) [2] . The DBP-25(OH)D 3 complex is taken up by megalin and cubilin in the kidney and converted by 1α-hydroxylase (Cyp27b1) into 1.25(OH) 2 D 3 [3, 4] . Besides the classical role, 1.25(OH) 2 D 3 has broad immunoregulatory effects on innate and adaptive immune responses. [5] . The nuclear vitamin D receptor (VDR) and Cyp27b1 are expressed in most immune cells e.g. T and B lymphocytes, monocytes, Mφ, natural killer cells and dendritic cells [6, 7] . Through interaction between VDR and 1.25(OH) 2 D 3 and heterodimerization with retinoic X receptor (RXR), this complex binds to the Vitamin D responsive element (VDRE) in the promoter region of specific genes enabling gene transcription responsible for cell regulation and differentiation [7, 8] . Mφ are plastic, heterogenic immune cells that are able to polarise into specific phenotypes during inflammatory conditions, whether low-grade, autoimmune or infectious [9, 10] . The effects of 25(OH)D 3 and 1.25(OH) 2 D 3 on Mφ polarisation have been examined in cell lines e.g. human THP-1 and murine RAW 264.7, however data are not consistent and detailed knowledge about the effects of vitamin D 3 on human Mφ is lacking, although current evidence suggests anti-inflammatory effects [11] [12] [13] . Supra-physiological concentrations of 1.25(OH) 2 D 3 carry the risk of hypercalcemia, restricting high dose anti-inflammatory treatment. However, technologies for specific targeting of 1.25 (OH) 2 D 3 to Mφ may circumvent these obstacles [12, 13] . In this study, we have therefore investigated the anti-inflammatory effects of both physiological and supra-physiological concentrations of 25(OH)D 3 and 1.25(OH) 2 D 3 in Mφ.
Materials and methods

Purification of human mononuclear cells from buffy coats
Human buffy coats were collected anonymized during routine blood donations from volunteer donors at the Blood Bank of Aarhus University Hospital. According to Danish law, collection of buffy coats does not require separate ethical approval. 50 mL buffy coats were diluted 1:1 with 0.9% NaCl and 25 mL were carefully layered to 15 mL Histopaque-1077 (Sigma-Aldrich, Soeborg, Denmark) and centrifuged at 400 g at RT for 30 minutes. The opaque interface containing mononuclear cells was transferred to new tubes, added D-PSB/2%FCS/1mM EDTA and centrifuged at 200g for 10 minutes at RT following repeated wash/centrifuge step. Monocytes were purified by plastic adherence or CD14 positive selection. For plastic adherence 2 x 10 6 cells/mL were incubated in T75 flasks with in RPMI 1640/PS/10% human serum (Gibco, ThermoFisher Scientific, Hvidovre, Denmark) for 1h. Non-adherent cells were removed and adherent monocytes received fresh medium containing 100 ng/mL M-CSF and 10 ng/mL GM-CSF (both from PeproTech, Stockholm, Sweden) for Mφ differentiation. For CD14 positive selection, EasySep Human CD14 Positive Enrichment kit (Cat. #18058, Stemcell Technologies, Cambridge, England) was applied. Mononuclear cell suspension was prepared at a concentration of 5x10 7 cells/mL in D-PBS/2%FCS/1mM EDTA. EasySep protocol for CD14
positive selection was applied for the remaining purification of monocytes. Monocytes received fresh medium every second day and matured to fully differentiated Mφ after 6-days incubation period.
Stimulation of Mφ with 25(OH)D 3 and 1.25(OH) 2 D 3
Differentiated Mφ were collected, counted and tested for viability (Nucleo-Counter NC-250, ChemoMetec, Alleroed, Denmark). Two mL 1x10^6 MD-Mφs/mL were seeded per well (in six-well plates) and incubated in fresh medium (RPMI/PS/10%FCS/100ng/mL M-CSF/10 ng/ mL GM-CSF) for 24 hours to adhere at 37˚C in 5% CO 2 /95% air. [14] . mRNA ratios of target gene/house-keeping gene were normalized to untreated control. Table 1 contains forward/reverse primers and primer specific annealing temperatures (Table 1) . 
CCACTTCTGCTTGGGGTCAGC
List of target gene forward and reverse primer along with their specific annealing temperatures applied for RT-qPCR. 
Enzyme-linked immunosorbent assay (ELISA) for TNF-α and IL-6
For measurements of TNF-α and IL-6 in Mφ culture supernatants, Human TNF-α DuoSet ELISA kits (DY210-05) and Human IL-6 DuoSet ELISA kits (DY206-05) (R&D systems Biotechne, Abingdon, United Kingdom) were applied and manufacture's standard protocol was followed.
Statistical analysis
Graph Pad Prism 7 software (La Jolla, USA) was applied to prepare graphs and statistical analyses. (Fig 1C, S1  Fig and S2 Fig) . The effects were comparable to the inhibitory effects of dexamethasone. Also, MCP-1 and NF-κB mRNA gene expression was considerably inhibited by high dose 25(OH) D 3 and 1.25OH 2 D 3 compared to untreated control Mφ at all timepoints (Fig 1D and 1E, S1 Fig  and S2 Fig) comparable to the inhibitory effects of dexamethasone. High dose 25(OH)D 3 and 1.25OH 2 D 3 also inhibited IL-6 gene expression, however the effect was not as pronounced as seen with dexamethasone ( Fig 1F, S1 Fig and S2 Fig) .
Results
High dose vitamin D 3 inhibits constitutively expressed pro-inflammatory markers in unstimulated Mφ
High dose vitamin D 3 inhibits TNF-α and NF-κB in LPS stimulated Mφ
LPS strongly inhibited VDR gene expression but clearly up-regulated Cyp27b1 gene expression in Mφ similarly as reported previously [15] . Pre-treatment with 25(OH)D 3 and 1.25 (OH) 2 D 3 did not affect VDR gene downregulation, but 1.25(OH) 2 D 3 partly reverted Cyp27b1 gene upregulation (Fig 2A and 2B, S3 Fig and S4 Fig) . As, expected, LPS strongly induced gene expressions of pro-inflammatory markers TNF-α, NF-κB and IL-6 (20, 3 and 9-fold respectively at 12 hours), whereas there was no effect on MCP-1 expression (Fig 2C, 2E and 2F ).
Both 25(OH)D 3 and 1.25(OH) 2 D 3 significantly attenuated LPS induced TNF-α gene expression at 12 and 24 hours (Fig 2C, S3 Fig and S4 Fig) . Also, attenuation of NF-κB was observed by both 25(OH)D 3 and 1.25(OH) 2 D 3 at 12 hours (Fig 2E) , whereas no significant effect on induced MCP-1 or IL-6 expression was observed (Fig 2D-2F, S3 Fig and S4 Fig) .
High dose vitamin D 3 inhibits TNF-α protein release in LPS stimulated Mφ
We then examined TNF-α protein secretion to culture media by ELISA. These findings confirmed the attenuation of TNF-α gene expression, showing a significant reduction in TNF-α release in LPS stimulated Mφ. In LPS stimulated Mφ, a significant reduction was seen already after 12 hours and maintained at 24 h (Fig 3A and 3B) , whereas no significant change was observed in unstimulated Mφ after 12 hours, although a tendency was seen at 24 hours (Fig 3C  and 3D ). In addition, we also observed that high dose 25(OH)D 3 
Discussion
The main finding of this study was to show a significant inhibition of TNF-α expression in fully differentiated human monocyte-derived Mφ by vitamin D 3 both during normal and proinflammatory conditions. It has previously been shown that 1.25(OH) 2 Mφ are known for their plasticity and polarisation in accordance to the surrounding microenvironment [21] [22] [23] and are known to play important roles in the development and sustaining of chronic inflammatory diseases by the production of pro-inflammatory cytokines. Of notice, TNF-α is a key mediator of inflammation evidenced by the clinical effect of TNF-α blocking biological drugs. It is therefore compelling to explore the use of high-dose vitamin D for anti-inflammatory treatment in e.g. inflammatory liver disease [24] [25] and metabolic low-grade inflammatory conditions related to insulin resistance and type 2 diabetes, where these pro-inflammatory markers are also involved [26] [27] [28] . 
